for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adcock Ingram Holdings Limited

AIPJ.J

Latest Trade

5,700.00ZAc

Change

10.00(+0.18%)

Volume

477,862

Today's Range

5,584.00

 - 

5,704.00

52 Week Range

5,400.00

 - 

6,912.00

As of on the Johannesburg Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,690.00
Open
5,625.00
Volume
477,862
3M AVG Volume
8.11
Today's High
5,704.00
Today's Low
5,584.00
52 Week High
6,912.00
52 Week Low
5,400.00
Shares Out (MIL)
171.43
Market Cap (MIL)
10,000.68
Forward P/E
12.32
Dividend (Yield %)
3.51

Next Event

Adcock Ingram Holdings Ltd Annual Shareholders Meeting

Latest Developments

More

Adcock Ingram Annual Gross Profit Rises 11%

Adcock Ingram Says BB Investment Co Now Holds 50.14% Of Issued Ordinary Shares Of Co

Adcock Ingram Says BB Investment Co Holds 51.14% Of Total Issued Ordinary Shares Of Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adcock Ingram Holdings Limited

Adcock Ingram Holdings Limited is a healthcare company. The Company is a pharmaceutical manufacturer, which manufactures, markets and distributes a range of healthcare products, and supplies to both the private and public sectors of the market. The Company's segments include Over the Counter (OTC), Consumer, Prescription and Hospital. The OTC segment focuses primarily on brands sold predominantly in the pharmacy market. The Consumer segment is engaged in the fast moving consumer goods (FMCG) space. The Prescription segment markets products prescribed by medical practitioners. The Hospital segment operates as a supplier of hospital and critical care products, including intravenous solutions, blood collection products and renal dialysis systems. The Company's products include Allergex Non-Drowsy, Panado Paed Syrups, Probiflora Infant, Cepacol, Medi-Keel A, Adco-Acyclovir Topical Cream and Adco-Normospor Vaginal Cream.

Industry

Retail (Drugs)

Contact Info

1 New Road New Road & 7th Street Midrand

+27.11.6350000

http://www.adcock.co.za/

Executive Leadership

Lindsay Peter Ralphs

Non-Executive Chairman of the Board

Andrew G. Hall

Chief Executive Officer, Executive Director

Dorette Neethling

Chief Financial Officer, Executive Director

Ntando Simelane

Head of Legal, Company Secretary

Tobie Krige

Managing Director – Distribution

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, ZAR)

2017

6.0K

2018

6.6K

2019

7.1K

2020(E)

7.7K
EPS (ZAR)

2017

3.089

2018

3.877

2019

4.228

2020(E)

4.617
Price To Earnings (TTM)
13.72
Price To Sales (TTM)
1.41
Price To Book (MRQ)
2.27
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
16.48
Return on Equity (TTM)
11.13

Latest News

Latest News

UPDATE 1-South African drugmaker Adcock profit jumps, offloads Ghana investment

South African pharmaceutical firm Adcock Ingram Holdings Ltd said on Wednesday full-year earnings rose 10.6% and that it disposed of its investment in Ghana.

S.Africa's Adcock Ingram posts higher FY profit, unloads Ghana investment

South African pharmaceutical firm Adcock Ingram Holdings Ltd said on Wednesday full-year earnings rose 10.6% and that it disposed of its investment in Ghana.

BRIEF-Adcock Ingram Says Genop Holdings Deal Now Unconditional ​

* ADCOCK INGRAM - CONDITIONS PRECEDENT, INCLUDING REGULATORY APPROVALS, MET; GENOP HOLDINGS DEAL NOW UNCONDITIONAL

BRIEF-Adcock Ingram Says HY HEPS From Continuing Operations Increases 33 Pct​

* HY HEADLINE EARNINGS PER SHARE FROM CONTINUING OPERATIONS INCREASES 33%

BRIEF-Adcock ‍Expects HY HEPS Between 188.6 And 193.6 Cents Per Share

* EXPECTS HY HEPS TO REFLECT AN INCREASE OF BETWEEN 27% AND 30%, BEING 188.6 CENTS AND 193.6 CENTS COMPARED TO PREVIOUS PERIOD Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

South Africa's Adcock Ingram sees HY headline earnings up 27 pct

South African drugmaker Adcock Ingram forecast on Tuesday an at least 27 percent rise in half-year headline earnings per share.

CORRECTED-BRIEF-Adcock Ingram Sees HY HEPS Up At Least 40 Cents

* EXPECTS HEPS FOR SIX-MONTH PERIOD ENDED DEC. 31 TO BE NOT LESS THAN 27% (40 CENTS) HIGHER THAN CORRESPONDING REPORTING PERIOD

South Africa's Adcock Ingram to acquire Genop Holdings

South African drugmaker Adcock Ingram will buy contact lenses, surgical and skincare products supplier Genop Holdings, it said on Tuesday, a deal that gives it a company with 400 million rand ($31 million) in annual sales.

BRIEF-Adcock Ingram Holdings says increase of 7% in FY turnover to 5,936 mln rand

* DECLARED FINAL DIVIDEND OF 76 CENTS PER SHARE FOR YEAR ENDED 30 JUNE 2017

BRIEF-Adcock Ingram Holdings sees FY HEPS between 310 cents and 313 cents

* SEES FY HEPS TO BE BETWEEN 310 CENTS AND 313 CENTS PER SHARE, INCREASE OF BETWEEN 36% AND 37% COMPARED TO PRIOR YEAR Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Adcock Ingram expects FY HEPS to be not less than 297.3 cents

* Company expects EPS and HEPS for year ended 30 June 2017 to be not less than 324.5 cents and 297.3 cents Source text for Eikon: Further company coverage:

BRIEF-Adcock Ingram to acquire Virtual Logistics

* Acquisition will be effective April 2017 Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Adcock Ingram says half-year HEPS up 52 pct

* Interim results for six months ended Dec. 31 2016 and cash dividend declaration

BRIEF-Adcock Ingram sees HEPS for six months ended Dec. 31 up between 45-49 pct

* HEPS for six months ended Dec 31, will reflect an increase of between 45 pct and 49 pct being, 145 cents and 149 cents per share (December 2015:99.8 cents) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Adcock Ingram sees at least 40 pct higher six-month HEPS

* HEPS for six-month period ended Dec.31 2016 will be not less than 40 pct (40 cents) higher than previous corresponding reporting period

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up